What question did this study set out to answer?

To investigate the impact of oral nanocurcumin on HPV infection clearance among women with high-risk HPV results.

April 11, 2026

Evaluating Nanocurcumin’s Influence on Human Papillomavirus Clearance and Cervical Smear Diagnostic Accuracy in High-Risk HPV Patients: A Randomized Clinical Trial

SNSomayeh NikfarArak University of Medical Sciences BKBehzad KhansarinejadArak University of Medical Sciences MMMaryam MohsenikiaIslamic Azad University, Tehran

Puntos clave

To investigate the impact of oral nanocurcumin on HPV infection clearance among women with high-risk HPV results.
Double-blind randomized clinical trial design
Participants were women with high-risk HPV test results
Participants divided into two groups: one receiving oral nanocurcumin (80 mg/d) and standard treatment, the other receiving placebo and standard treatment
Treatment duration was 4 months
HPV clearance and adverse effects monitored as primary and secondary outcomes
HPV clearance rate in the intervention group was 75.0%, compared to 42.8% in the placebo group
Statistically significant difference with a P value of 0.026, indicating nanocurcumin's beneficial effect
Clearance rates for HPV subtype 16 were 71.4% in the nanocurcumin group vs. 50.0% in the placebo group
For subtype 18, clearance rates were 77.8% vs. 37.5% between groups
Minimal major adverse events reported during the study period indicating safety of nanocurcumin treatment

Resumen

Objectives: Human papilloma virus (HPV) is the primary cause of cervical cancer, and its prevention is crucial in reducing the risk of developing this cancer. To explore potential preventive measures, we conducted a double-blind randomized clinical trial aiming at investigating the impact of oral nanocurcumin on HPV infection clearance in women who had high-risk results from HPV genotyping. Materials and Methods: We enrolled women with high-risk HPV test results as participants in this study. Through a random assignment process, the participants were divided into two groups: one group received oral nanocurcumin (80 mg/d) along with standard treatment, while the other group received a placebo and standard treatment. The duration of the treatment period was 4 months. HPV clearance was the primary outcome measure, and we also closely monitored and recorded any adverse effects experienced by the patients as the secondary outcome. Results: In the intervention group, we observed an HPV clearance rate of 75.0%, compared to 42.8% in the placebo group. This difference was statistically significant, with a P value of 0.026, indicating a beneficial effect of oral nanocurcumin in promoting HPV clearance. For specific HPV subtype 16, the clearance rate was higher in the nanocurcumin intervention group (71.4%) compared to the placebo group (50.0%). Similarly, for HPV subtype 18, the nanocurcumin intervention group showed a clearance rate of 77.8%, while the placebo group had a clearance rate of 37.5%. Although the sub-group analysis did not yield statistically significant differences (P > 0.05), the observed difference indicated a potential beneficial effect of nanocurcumin. Conclusions: Our study suggests that oral nanocurcumin has the potential to enhance HPV infection clearance. Furthermore, the treatment with oral nanocurcumin appears to be safe, as we observed minimal major adverse events reported during the study period.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo